Physician profile
Peter Dan Sliskovich
NPI 1811970015
$2,473.54
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $455 · 2021: $788.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $624.14 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $463.80 | 2019-2021 | |
| Amgen INC. | $149.44 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $141.99 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $121.87 | 2021 | |
| Esperion Therapeutics, INC. | $100.74 | 2021 | |
| Eisai INC. | $98.84 | 2021 | |
| Horizon Therapeutics Plc | $86.41 | 2019-2021 | |
| Abbvie INC. | $85.07 | 2021 | |
| Arbor Pharmaceuticals, INC. | $69.35 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $69.04 | 2020-2021 | |
| Genzyme Corporation | $60.00 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.29 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $40.35 | 2019 | |
| Astellas Pharma US INC | $37.41 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $37.06 | 2020-2021 | |
| Pfizer INC. | $36.89 | 2019 | |
| Bausch Health US, LLC | $34.34 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.44 | 2021 | |
| Emergent Biosolutions INC. | $23.19 | 2019 | |
| Merck Sharp & Dohme LLC | $20.45 | 2021 | |
| Optinose US, INC. | $20.40 | 2019 | |
| Aytu Biopharma, INC. | $16.60 | 2021 | |
| Alfasigma USA, INC. | $16.51 | 2020 | |
| Glaxosmithkline, LLC. | $15.56 | 2019 | |
| Redhill Biopharma INC. | $13.88 | 2020 | |
| Lilly USA, LLC | $12.48 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sliskovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.